ReviewInternational journal of nanomedicine2026
Nanodelivery of Traditional Chinese Medicine Monomers: An Emerging Strategy to Reprogram the Immunosuppressive Tumor Microenvironment.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cellular and Molecular Mechanisms of Berberine in Cancer Therapy: Recent Advances.Archiv der Pharmazie · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tumor microenvironment (TME), a highly complex and dynamic system, plays a central role in tumor progression and resistance to immunotherapy. Key immunosuppressive cell populations within the TME, including tumor-associated macrophages (TAMs), myeloid-derived suppressor cells (MDSCs), and regulatory T cells (Tregs), contribute to immune evasion through complex cytokine signaling and cellular crosstalk. These factors significantly limit the therapeutic efficacy of immune checkpoint inhibitors and other immunotherapies, particularly in "cold" tumors with poor immune infiltration. Traditional Chinese medicine (TCM) monomers have emerged as promising immunomodulatory agents due to their multi-target capability, favorable safety profiles, and ability to remodel the immune landscape. TCM compounds such as curcumin, berberine, resveratrol, and ginsenosides can modulate the recruitment, polarization, or function of TAMs, MDSCs, and Tregs. However, their clinical translation is hindered by the central challenge of poor solubility, low bioavailability, and limited tumor targeting capability. Nanotechnology provides a breakthrough strategy to address this core issue. Recent advances in nanotechnology offer effective solutions by enabling the encapsulation of TCM monomers into nano-delivery systems such as liposomes, polymeric nanoparticles, inorganic carriers, and biomimetic vesicles which enhance drug stability, promote tumor-specific accumulation, and allow controlled release. These integrated systems potentiate the pharmacological effects of TCM agents. Moreover, they help overcome immune resistance mechanisms within the TME. This review systematically examines the immunosuppressive roles of TAMs, MDSCs, and Tregs, summarizes the immunoregulatory actions of TCM monomers, and highlights cutting-edge nano-formulations developed to optimize their delivery. Together, these insights offer a novel framework for developing TCM-based nanomedicine strategies aimed at reprogramming the immunosuppressive TME and enhancing cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.